Wegovy With Insurance: What the Copay Actually Looks Like in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · As of May 2026 — confirm current pricing directly with the pharmacy or manufacturer.

Key Takeaways

• Commercial insurance copays for covered Wegovy: typically $25 to $200 per month; $0 to $25 with the savings card layered on
• The 2024 FDA cardiovascular indication (from the SELECT trial) opened Medicare coverage for patients with established cardiovascular disease and obesity
• Prior authorization is near-universal: plans verify BMI, comorbidities, and often prior weight-loss attempts before approving
• Employer plans vary widely; some exclude all anti-obesity medications, others cover Wegovy on preferred-brand tiers
• If insurance denies coverage, NovoCare direct-pay (~$499) and patient assistance ($0 for qualifying patients) are the next paths

Direct answer

With commercial insurance that covers Wegovy, monthly copays typically run $25 to $200 depending on plan tier; the Novo Nordisk savings card layered on top can drop eligible copays to $0 to $25. Medicare Part D now covers Wegovy for the cardiovascular indication (SELECT trial) in patients with obesity and established cardiovascular disease, with copays subject to the new $2,000 annual Part D out-of-pocket cap. Plans that exclude anti-obesity medications still leave NovoCare direct-pay (~$499) and patient assistance as options. Confirm current pricing directly with the pharmacy or manufacturer.

Table of contents

1. The commercial insurance copay landscape
2. Plan tier placement and what it means for cost
3. The Wegovy Savings Card mechanics
4. Prior authorization: criteria and how to clear it
5. Medicare Part D after the SELECT indication
6. Medicaid coverage of Wegovy
7. Employer plans that exclude anti-obesity medications
8. High-deductible plans and the math of pre-deductible Wegovy
9. Appeals when prior auth is denied
10. The decision framework
11. FAQ
12. Sources

The commercial insurance copay landscape

Real Wegovy copay distributions from May 2026 across major commercial payers:

Plan type	Typical monthly copay (after savings card)
Preferred brand tier	$0 to $25
Non-preferred brand tier	$25 to $80
Specialty tier (coinsurance)	$80 to $300
High-deductible pre-deductible	$900 to $1,100 (full negotiated rate)
Excluded from coverage	Not covered; alternative pathways needed

The difference between $25 and $300 reflects plan design, not list price. Patients can sometimes shop plans during open enrollment based on Wegovy coverage if anti-obesity medications are a priority.

Plan tier placement and what it means for cost

The tier a plan places Wegovy on determines whether you pay a fixed copay or a percentage coinsurance:

• Preferred brand: typically a flat copay ($25 to $80 before savings card)
• Non-preferred brand: typically a higher flat copay ($60 to $200)
• Specialty: typically a coinsurance percentage (20 to 40 percent of negotiated price), often capped per month

Specialty-tier placement can produce surprisingly high copays. A 30 percent coinsurance on a $1,200 negotiated rate is $360 per month before any savings card. Patients on specialty-tier Wegovy should verify what their plan allows and how the savings card stacks.

The Wegovy Savings Card mechanics

The Wegovy Savings Card in May 2026:

• Commercial insurance with Wegovy coverage: eligible copays as low as $0 per month, subject to caps
• Maximum monthly savings: up to $225 per fill
• Annual savings cap: $3,500
• Not eligible: Medicare, Medicaid, TRICARE, VA, or other government-funded programs
• Insurance-doesn't-cover tier: discounted price (typically around $650 per month, subject to annual cap)
• Activation: through NovoCare.com or printed cards from prescribers

The card is stacking on top of insurance benefits. Patients should activate before the first fill to capture savings from the start.

Prior authorization: criteria and how to clear it

Nearly all plans require prior authorization for Wegovy. Common required elements:

• BMI documentation (most plans require 30+; some require 35+ for first-line coverage)
• Comorbidity documentation if BMI is 27-29 (hypertension, dyslipidemia, type 2 diabetes, sleep apnea)
• Documented prior weight-loss attempts (6+ months of diet/exercise sometimes required)
• Sometimes step therapy through phentermine, orlistat, or another agent
• For Medicare: cardiovascular indication documentation if pursuing SELECT-pathway coverage

Clinicians experienced with Wegovy prior authorization clear approval in 60 to 80 percent of first submissions. Common denials trace to incomplete BMI/comorbidity documentation or missing step-therapy records. Appeals with additional documentation often succeed.

Medicare Part D after the SELECT indication

The FDA's March 2024 approval of Wegovy for reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity changed Medicare's coverage landscape. Medicare Part D cannot cover drugs for weight loss alone, but can cover them for other indications.

For Medicare patients with both obesity and established cardiovascular disease (prior MI, stroke, or symptomatic peripheral artery disease):

• Wegovy may be covered under the cardiovascular indication
• Prior authorization typically requires documentation of CVD history
• Copays vary by plan but are subject to the $2,000 annual Part D out-of-pocket cap in 2026
• The Medicare Prescription Payment Plan lets patients spread copay costs across the year

Patients with obesity but no CVD do not currently have a Medicare pathway for Wegovy. The Treat and Reduce Obesity Act, which would expand Medicare coverage of anti-obesity medications more broadly, has not passed.

Medicaid coverage of Wegovy

State Medicaid programs vary considerably:

• About one-third of state Medicaid programs cover Wegovy with prior authorization as of May 2026
• Coverage typically requires BMI 30+ and documented prior weight-loss attempts
• Step therapy through metformin, phentermine, or older anti-obesity medications is common
• Quantity limits and refill restrictions apply in most states

Patients on Medicaid should check their state's preferred drug list for current status. The list of covering states has been expanding through 2025-2026.

Employer plans that exclude anti-obesity medications

Many employer-sponsored insurance plans exclude weight-loss medications as a deliberate design choice. The exclusion may apply to all anti-obesity medications or specifically to GLP-1 agents.

For patients with these plans, options include:

• The Wegovy Savings Card's insurance-doesn't-cover tier (around $650 per month)
• NovoCare direct-pay (~$499)
• Novo Nordisk Patient Assistance Program ($0 for income-qualifying patients)
• Compounded semaglutide ($199-$399)
• Open-enrollment switch to a plan that covers Wegovy (if available)

The SELECT cardiovascular indication has nudged some previously excluding employers to add coverage, particularly for patients with documented cardiovascular disease.

High-deductible plans and the math of pre-deductible Wegovy

High-deductible health plans charge the patient the full negotiated rate until the deductible is met. For Wegovy, this typically means $900 to $1,100 per month for the first one to three months of the calendar year.

Strategies for high-deductible patients:

• Use the Wegovy Savings Card to apply some discount even pre-deductible
• Consider whether prepaying multiple months (where allowed) lets the deductible clear faster
• If on a Health Savings Account, use HSA dollars for the pre-deductible cost
• If pre-deductible cost is unaffordable, use NovoCare direct-pay (~$499) until the deductible clears

Appeals when prior auth is denied

Denials are not final. The appeals process typically allows:

1. First appeal with additional documentation (BMI charts, comorbidity records, prior attempt documentation)
2. Second-level appeal if first denied
3. Independent external review if internal appeals exhausted

Common winning arguments in appeals: documented prior weight-loss attempts spanning 6+ months, comorbidity documentation including A1C trajectories or blood pressure trends, sleep study data, and clinician statements of medical necessity. Patients with cardiovascular history should explicitly invoke the SELECT cardiovascular indication if appropriate.

The decision framework

If your plan covers Wegovy: complete prior auth, activate the savings card, and expect $0 to $80 monthly. If denied, appeal with full documentation.

If your plan excludes Wegovy but you have Medicare with established CVD: ask about the SELECT cardiovascular pathway.

If your plan excludes Wegovy and you do not qualify for the CVD pathway: use NovoCare direct-pay (~$499), apply for patient assistance if income-eligible, or consider compounded semaglutide.

If you are on a high-deductible plan: budget for pre-deductible Wegovy or use NovoCare direct-pay until the deductible clears.

If you have employer coverage during open enrollment: review whether other plan options offer better Wegovy coverage if anti-obesity treatment is a priority.

FAQ

How much is Wegovy with insurance in 2026? Typically $25 to $200 per month; $0 to $25 with the savings card on commercial insurance.

Does Medicare cover Wegovy? For the cardiovascular indication (established CVD + obesity), yes. For weight loss alone, no.

What is the Wegovy Savings Card and how does it stack with insurance? A commercial-insurance copay card that drops eligible copays to as low as $0. Annual cap $3,500.

Why was my Wegovy prior authorization denied? Common reasons: BMI below plan threshold, insufficient documented weight-loss attempts, missing comorbidity documentation. Appeals often succeed.

What insurance tier does Wegovy sit on? Usually non-preferred brand or specialty; some plans use preferred brand.

Does insurance cover Wegovy for cardiovascular risk? After March 2024 FDA approval for cardiovascular event reduction, many plans expanded coverage for patients with established CVD and obesity.

How do I get my insurance to cover Wegovy? Document BMI and comorbidities, complete prior authorization, appeal denials. Step therapy may be required.

What if my employer plan excludes anti-obesity medications? NovoCare direct-pay (~$499), patient assistance, or compounded semaglutide are the typical paths.

How long does prior authorization take? 3 to 14 days for standard requests; 24 to 72 hours for urgent requests.

Can I appeal a Wegovy denial successfully? Yes. Many denials are reversed on appeal with additional documentation.

Does the savings card work if my insurance doesn't cover Wegovy? An "insurance doesn't cover" tier exists at around $650 per month, subject to annual cap.

Sources

1. Novo Nordisk. Wegovy savings card and prescribing information. NovoCare.com. 2026.
2. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information and cardiovascular indication approval. 2024.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. New England Journal of Medicine. 2023 (SELECT trial).
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021 (STEP 1).
5. Centers for Medicare and Medicaid Services. Medicare Part D coverage update following SELECT trial. CMS.gov. 2024-2025.
6. Kaiser Family Foundation. Employer Health Benefits Survey 2025. GLP-1 and anti-obesity medication coverage.
7. State Medicaid agencies. Preferred drug list documentation for semaglutide weight-management products. Multiple states 2025-2026.
8. American Heart Association. SELECT trial implications for cardiovascular disease management. 2024.
9. Inflation Reduction Act of 2022. Medicare Part D provisions.
10. Endocrine Society. Clinical practice guideline on pharmacological management of obesity. 2024.
11. Novo Nordisk Patient Assistance Program documentation. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends operates as a digital health platform; we connect patients with independent licensed providers and partnered pharmacies. We are not a pharmacy and do not prescribe medication. The treating clinician makes all medical decisions following individual evaluation.

Compounded Medication Notice. References to compounded semaglutide describe products prepared by 503A state-licensed compounding pharmacies in response to individual prescriptions. Compounded preparations are not FDA-approved, are not interchangeable with brand Wegovy, and have not undergone FDA drug review.

Results Disclaimer. Pricing and program data cited reflect public information available in May 2026. Insurance copays, plan tiers, prior authorization criteria, and manufacturer programs change. Confirm current pricing and coverage directly with your insurer, pharmacy, or Novo Nordisk.

Trademark Notice. Wegovy, Ozempic, and NovoCare are registered trademarks of Novo Nordisk A/S. Zepbound, Mounjaro, Lilly Direct, and Lilly Cares are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by either manufacturer.